SEARCH

SEARCH BY CITATION

References

  • Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws American Association of Oral Maxillofacial Surgeons (2007). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65: 369377.
  • Allen M (2011). The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. Odontology 99: 817.
  • Arce K, Assael LA, Weissman JL et al (2009). Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 67(Suppl. 1): 7584.
  • Bagán J, Blade J, Cozar JM et al (2007). Recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Patol Oral Cir Bucal 12: 336340.
  • Bagán JV, Jimenez Y, Diaz JM et al (2009). Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification. Oral Oncol 45: 645646.
  • Berenson JR, Lichtenstein A, Porter L et al (1996). Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488.
  • Berenson JR, Hillner BE, Kyle RA et al (2002). American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 20: 37193736.
  • Colella G, Campisi G, Fusco V (2009). American Association of Oral and Maxillofacial Surgeons position paper: bisphosphonate-Related Osteonecrosis of the Jaws-2009 update: the need to refine the BRONJ definition. J Oral Maxillofac Surg 67: 26982699.
  • Estilo CL, Fornier M, Farooki A et al (2008). Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26: 40374038.
  • Fedele S, Porter SR, D’Aiuto F et al (2010). Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series. Am J Med 123: 10601064.
  • Fizazi K, Carducci M, Smith M et al (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377: 813822.
  • Fusco V, Galassi C, Berruti A et al (2011). Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol 29: 521522.
  • Hellstein JW, Adler RA, Edwards B et al (2011). Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis. J Am Dent Assoc 142: 12431251.
  • Hortobagyi GN, Theriault RL, Porter L et al (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335: 1785.
  • Hutchinson M, O’Ryan F, Chavez V et al (2010). Radiographic findings in bisphosphonate-treated patients with stage 0 disease in the absence of bone exposure. J Oral Maxillofac Surg 68: 22322240.
  • Junquera L, Gallego L (2008). Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 66: 15161517.
  • Khan AA, Sándor GK, Dore E et al (2008). Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 35: 13911397.
  • Khosla S, Burr D, Cauley J et al (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22: 1479.
  • Kumar SKS, Gorur A, Schaudinn C et al (2010). The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep 8: 4048.
  • Lazarovici TS, Yahalom R, Taicher S et al (2009). Bisphosphonaterelated osteonecrosis of the jaws: A single-center study of 101 patients. J Oral Maxillofac Surg, 67: 850.
  • Marx RE (2003). Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61: 11151117.
  • Mawardi H, Treister N, Richardson P et al (2009). Sinus tracts – an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg 67: 593601.
  • McMahon RE, Bouquot JE, Glueck CJ et al (2007). Staging bisphosphonate-related osteonecrosis of the jaw should include early stages of disease. J Oral Maxillofac Surg 65: 18991900.
  • Mehrotra B, Ruggiero S (2006). Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 1: 356360.
  • Migliorati CA, Casiglia J, Epstein J et al (2005). Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136: 16581668.
  • Ruggiero SL (2011). Bisphosphonate-related osteonecrosis of the jaw: an overview. Ann N Y Acad Sci 1218: 3846.
  • Ruggiero SL, Drew SJ (2007). Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 86: 10131021.
  • Ruggiero SL, Mehrotra B (2009). isphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management. Annu Rev Med 60: 18.118.2.
  • Ruggiero SL, Mehrotra B, Rosenberg TJ et al (2004). Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62: 527.
  • Ruggiero SL, Fantasia J, Carlson E (2006). Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102: 433441.
  • Ruggiero SL, Dodson TB, Assael LA et al (2009). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 67(Suppl. 5): 212.
  • Sarasquete ME, González M, San Miguel JF (2009). Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. Oral Dis 15: 382387.
  • Vescovi P, Nammour S (2010). Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) therapy. A critical review. Minerva Stomatol 59: 181203, 204–13.
  • Woo SB, Mawardi H, Treister N (2008). Comments on ‘Osteonecrosis of the jaws in intravenous bisphosphonate use: proposal for a modification of the clinical classification’. Oral Oncol 45: 740.
  • Yarom N, Yahalom R, Shoshani Y et al (2007). Osteonecrosis of the jaw induced by orally administered bisphosphonates: incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18: 13631370.
  • Yaroma N, Fedele S, Lazarovici TS, Elad S (2010). Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg 68: 705.
  • Yaromb N, Elad S, Madrid C, Migliorati CA (2010). Osteonecrosis of the jaws induced by drugs other than bisphosphonates - a call to update terminology in light of new data. Oral Oncol 46: 1.
  • Yoneda T, Hagino H, Sugimoto T et al (2010). Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeon. J Bone Miner Meta 28: 365383.